Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: A retrospective study of the TUTHYREF network

European Journal of Endocrinology

Volumn 170, Issue 4, 2014, Pages 575-582

  Massicotte, Marie Hélène ^a,b   Brassard, Maryse ^c   Claude Desroches, Médéric ^d   Borget, Isabelle ^a   Bonichon, Françoise ^e   Giraudet, Anne Laure ^f   Cao, Christine Do ^g   Chougnet, Cécile N ^a   Leboulleux, Sophie ^a   Baudin, Eric ^a   Schlumberger, Martin ^a   De La Fouchardière, Christelle ^h  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e INSTITUT BERGONIÉ   (France)

^f INSTITUT CURIE   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CABOZANTINIB; LENVATINIB; MOTESANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VANDETANIB;

ADULT; AGED; ANOREXIA; ARTICLE; BODY WEIGHT DISORDER; BONE METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FRANCE; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NEPHROTIC SYNDROME; PLEURA METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QT PROLONGATION; RETROSPECTIVE STUDY; STOMATITIS; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID PARAFOLLICULAR CELL; TORSADE DES POINTES; TUMOR DIFFERENTIATION; WEIGHT REDUCTION;

ADENOCARCINOMA; ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PIPERIDINES; PLEURAL NEOPLASMS; PROTEIN-TYROSINE KINASES; PYRROLES; QUINAZOLINES; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84899477812     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0825     Document Type: Article

References (22)

1. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F et al. Long term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. Journal of Clinical Endocrinology and Metabolism 2006 91 2892-2899. (doi:10.1210/jc.2005-2838)
2. Chougnet C, Brassard M, Leboulleux S, Baudin E & Schlumberger M. Molecular targeted therapies for patients with refractory thyroid cancer. Clinical Oncology 2010 22 448-455. (doi:10.1016/j.clon. 2010.04.008)
3. De La Fouchardière C & Droz JP. Targeted therapies and thyroid cancer: an update. Anti-Cancer Drugs 2011 22 688-699. (doi:10.1097/CAD. 0b013e32834319c7)
4. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ et al. Phase II trial of sorafenib in advanced thyroid cancer. Journal of Clinical Oncology 2008 26 4714-4719. (doi:10.1200/JCO.2008.16.3279)
5. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M et al. Phase II trial of sorafenib in metastatic thyroid cancer. Journal of Clinical Oncology 2009 27 1675-1684. (doi:10.1200/JCO.2008.18.2717)
6. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE & Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clinical Cancer Research 2010 16 5260-5268. (doi:10.1158/1078-0432. CCR-10-0994)
7. Cohen EE, Needles BM, Cullen KJ, Wong SJ, Wade JL, Ivy SP, Villaflor VM, Seiwert TY, Nichols K & Vokes EE. Phase 2 study of sunitinib in refractory thyroid cancer. Journal of Clinical Oncology 2008 26 (Suppl) 6025 (abstract).
8. Brose MS, Nutting C, Jarzab B, Elisei R, Siena S, Bastholt L, De La Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the phase 3 DECISION trial. Journal of Clinical Oncology 2013 31 (Suppl) 4 (abstract).
9. Leboulleux S, Bastholt L, Krause T, De La Fouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F, Leenhardt L, Soufflet C et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncology 2012 13 897-905. (doi:10.1016/S1470-2045 (12) 70335-2)
10. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. Journal of Clinical Oncology 2010 28 2323-2330. (doi:10.1200/JCO.2009.25.0068)
11. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. Journal of Clinical Oncology 2012 30 134-141. (doi:10.1200/JCO.2011.35.5040)
12. Elisei R, Schlumberger MJ, Müller S, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC et al. Cabozantinib in progressive medullary thyroid carcinoma. Journal of Clinical Oncology, 2013.
13. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1). European Journal of Cancer 2009 45 228-247. (doi:10.1016/j.ejca.2008.10.026)
14. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI & Busaidy NL. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. Journal of Clinical Endocrinology and Metabolism 2010 95 2588-2595. (doi:10.1210/jc.2009-1923)
15. Takahashi D, Nagahama K, Tsuura Y, Tanaka H & Tamura T. Sunitinibinduced nephrotic syndrome and irreversible renal dysfunction. Clinical and Experimental Nephrology 2012 16 310-315. (doi:10.1007/s10157-011-0543-9)
16. Zimmermann K, Schmittel A, Steiner U, Asemissen AM, Knoedler M, Thiel E, Miller K & Keilholz U. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009 76 350-354. (doi:10.1159/000209961)
17. Cabanillas ME, Brose MS, Ramies DA, Lee Y, Miles D & Sherman SI. Antitumor activity of cabozantinib (XL184) in a cohort of patients (PTS) with differentiated thyroid cancer (DTC). Journal of Clinical Oncology 2012 30 (Suppl) 5547 (abstract).
18. Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, McCaffrey JC, Newbold K, Allison R, Martins R et al. A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC). Journal of Clinical Oncology 2012 30 (Suppl) 5591 (abstract).
19. Sherman SI, Jarzab B, Cabanillas ME, Licitra LF, Pacini F, Martins R, Robinson B, Ball D, McCaffrey J, Shah MH et al. A phase II trial of the multi-targeted kinase inhibitor, lenvatinib (E7080), in advanced radioiodine-refractory differentiated thyroid cancer (DTC). Journal of Clinical Oncology 2011 29 (Suppl) 5503 (abstract).
20. Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, Weijers K, Pereira AM, Huijberts M, Kapiteijn E et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. European Journal of Endocrinology 2009 161 923-931. (doi:10.1530/EJE-09-0702)
21. Haissaguerre M, Leboulleux S, Bonichon F, Borget I, Chougnet CN, Al Ghuzlan A, Hartl DM, Mirghani H, Deandreis D, Baudin E et al. Impact of molecular targeted therapies in patients with bone metastases of differentiated thyroid carcinoma. Thyroid 2012 22 (Suppl 1) oral 9 (abstract).
22. Cabanillas ME, Hu MI, Durand JB & Busaidy NL. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. Journal of Thyroid Research 2011 2011. Artice ID 985780. (doi:10.4061/2011/985780)